Gemcitabine News and Research

RSS

Gemcitabine is the active ingredient in a drug that is used to treat pancreatic cancer that is advanced or has spread. It is also used together with other drugs to treat breast cancer that has spread, advanced ovarian cancer, and non-small cell lung cancer that is advanced or has spread. It is also being studied in the treatment of other types of cancer. Gemcitabine blocks the cell from making DNA and may kill cancer cells. It is a type of antimetabolite

IPIAD augments standard therapy for pancreatic ductal adenocarcinoma

A new research perspective was published in Oncoscience (Volume 11) on February 7, 2024, entitled, "IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone."

9 Feb 2024

Novel miRNA-based therapy shows promise for treatment of drug-resistant biliary tract cancer

Biliary tract cancers (BTCs) including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are becoming more prevalent globally.

30 Nov 2023

Landmark studies present new era for bladder cancer treatment

After 40 years of treating metastatic bladder cancer with chemotherapy as a primary treatment, scientists now present a new approach using immunotherapy combinations.

16 Nov 2023

Preclinical research points to a promising new treatment option for pancreatic cancer patients

Preclinical research published in the Journal for ImmunoTherapy of Cancer points to a promising new treatment option for people with pancreatic cancer.

10 Nov 2023

Trastuzumab deruxtecan offers added benefit for patients with HER2-low breast cancer

The antibody-drug conjugate trastuzumab deruxtecan is approved for various therapeutic indications. Since March 2023, it can also be used as monotherapy for the treatment of adults with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy at this disease stage or developed disease recurrence early after adjuvant chemotherapy.

31 Oct 2023

Chemotherapy plus immunotherapy improves survival in patients with metastatic urothelial cancer

A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.

22 Oct 2023

Inexpensive combo-chemotherapy found to be better tolerated than BCG for common bladder cancer

An on-going, worldwide shortage of bacillus Calmette-Guérin (BCG) means that many patients with a common and serious type of bladder cancer have limited access to this effective standard of care treatment.

28 Feb 2023

Four-drug chemotherapy regimen provides longer overall survival for metastatic pancreatic ductal adenocarcinoma

A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma.

20 Jan 2023

Addition of nab-paclitaxel to gemcitabine/cisplatin does not improve overall survival of patients with advanced biliary tract cancers

Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit for subsets of patients with locally advanced disease or gallbladder adenocarcinoma.

20 Jan 2023

Small antiviral molecules termed assembly modulators show therapeutic efficacy against cancer

In a new study, researchers evaluated the anti-cancer therapeutic efficacy of two structurally-unrelated small molecules, PAV-617 and PAV-951.

4 Oct 2022

Newly discovered gene marker may lead to a precision treatment for pancreatic cancer

Researchers at Mayo Clinic Comprehensive Cancer Center have identified a gene marker that may lead to a more effective, precision treatment for pancreatic ductal adenocarcinoma (PDAC).

22 Sep 2022

Chemo-immunotherapy combination shows promise against pancreatic cancer

A combination of chemotherapy with an immunotherapy meant to unleash the anticancer capacity of the immune system was effective against one of the hardest targets in cancer care, pancreatic cancer, in a national, randomized clinical trial led by researchers at the Perelman School of Medicine at the University of Pennsylvania, and sponsored by the Parker Institute for Cancer Immunotherapy.

6 Jun 2022

Novel drug combination can boost chemoimmunotherapy response in bladder cancer patients

Adding an anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumor growth, according to a proof-of-concept study led by Cedars-Sinai Cancer investigators.

28 Mar 2022

New therapy makes immunologically 'cold' tumors hot enough for immune attack

Pancreatic cancer is notoriously difficult to cure or even treat. Now, a new strategy devised by scientists at Albert Einstein College of Medicine has succeeded in making pancreatic tumors visible to the immune systems of mice and vulnerable to immune attack, reducing cancer metastases by 87%.

23 Mar 2022

Study: Ketogenic diet helps kill pancreatic cancer cells when combined with a triple-drug therapy

The findings of a new study suggest that a ketogenic diet -; which is low in carbohydrates and protein, but high in fat -; helps to kill pancreatic cancer cells when combined with a triple-drug therapy developed by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

22 Mar 2022

Biomarker could predict pathologic response to chemotherapy among bladder cancer patients

Long-term survival data from the first prospective, randomized biomarker validation trial in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery will be reported at the 2022 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (GU ASCO) on February 18, 2022.

15 Feb 2022

Ketogenic diet could enhance the efficacy of chemotherapy for pancreatic cancer, study shows

A Ludwig Cancer Research preclinical study has demonstrated that a common weight-loss diet could enhance the efficacy of chemotherapy for pancreatic cancer.

12 Feb 2022

Death rates from ovarian cancer are predicted to fall by 2022 in EU countries

Death rates from ovarian cancer are predicted to fall by 17% in the UK and by 7% in EU countries in 2022 compared to 2017, according to new research published in the leading cancer journal Annals of Oncology today (Wednesday).

27 Jan 2022

A class of FDA-approved drugs can effectively stop aggressive uterine cancer

A team of scientists led by the University of Michigan Health Rogel Cancer Center has found that a class of U.S. Food and Drug Administration-approved drugs can effectively stop a highly aggressive type of uterine cancer in its tracks, paving a quick path toward new treatment strategies for a deadly cancer with limited therapeutic options.

17 Dec 2021

Researchers analyze live bacteria from cystic lesions that are precursors to pancreatic cancer

Bacteria from the digestive system seem to have the potential to cause damage to pancreatic cells, increasing the risk of malignant tumors.

24 Nov 2021